Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma

The development of targeted inhibitors, vemurafenib and dabrafenib, has led to improved clinical outcome for melanoma patients with BRAF(V600E) mutations. Although the initial response to these inhibitors can be dramatic, sometimes causing complete tumor regression, the majority of melanomas eventua...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncogene
Main Authors: Yang, H, Kircher, D A, Kim, K H, Grossmann, A H, VanBrocklin, M W, Holmen, S L, Robinson, J P
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2017
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501768/
https://ncbi.nlm.nih.gov/pubmed/28263969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2016.526
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki